Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midodrine in HFrEF with Hypotension
NCT06405555Phase 3Recruiting
- Sponsor
- University of Ottawa Heart Institute
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of midodrine in heart failure with reduced ejection fraction (HFrEF), hypotension, sponsored by University of Ottawa Heart Institute. Started Aug 2026; status: recruiting.
02
Drugs
midodrine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)hypotension
Beyond the preview
Go deeper on NCT06405555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06405555.